Novartis Gets CDSCO Panel Nod to Study XXB750 in Patients With Heart Failure

Eligible participants will be randomized to receive either subcutaneous (s.c.) XXB750 or placebo; or sacubitril/valsartan for 16 weeks, and then followed-up for 8 weeks

However, this approval is subject to the condition that approximately 50% of sites and subjects should be enrolled from Govt. sites. Furthermore, the expert panel suggested that private study sites of university medical colleges only be included in the study.

XXB 750 is an experimental injected drug that targets natriuretic peptide (NPR1) and is developed to treat resistant hypertension. It was also tried for heart failure with reduced ejection fraction.

At the recent SEC meeting for Cardiovascular held on 9th January 2023, the expert panel reviewed the protocol presented by the drug major Novartis for the Phase II clinical trial of XXB750.

After detailed deliberation, the committee recommended the grant of permission to conduct the trial subject to the condition that

(1) Approximately 50% of sites and subjects shall be enrolled from Govt. sites.

(2) Private study sites of university medical colleges only shall be included in the study.

Also Read:Novo Nordisk Gets CDSCO Panel Nod to Study Ziltivekimab